Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Lyell Immunopharma Inc.

    NASDAQ: LYEL · Real-Time Price · USD
    11.24
    -2.23 (-16.56%)
    At close: Jun 05, 2025, 3:59 PM
    11.00
    -2.18%
    Pre-market: Jun 06, 2025, 08:41 AM EDT

    Lyell Immunopharma Statistics

    Share Statistics

    Lyell Immunopharma has 15.73M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 15.73M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 1.05%

    Owned by Institutions (%)

    n/a
    		 58.64%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 477,311

    FTD / Avg. Volume

    n/a
    		 684.83%

    Short Selling Information

    The latest short interest is 9.71M, so 3.29% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 9.71M

    Short % of Shares Out

    n/a
    		 3.29%

    Short % of Float

    n/a
    		 4.34%

    Short Ratio (days to cover)

    n/a
    		 14.2

    Valuation Ratios

    The PE ratio is -0.49 and the forward PE ratio is -1. Lyell Immunopharma's PEG ratio is -0.01.

    PE Ratio

    n/a
    		 -0.49

    Forward PE

    n/a
    		 -1

    PS Ratio

    n/a
    		 2743.4

    Forward PS

    n/a
    		 5801

    PB Ratio

    n/a
    		 0.44

    P/FCF Ratio

    n/a
    		 -1.03

    PEG Ratio

    n/a
    		 -0.01
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Lyell Immunopharma.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 7.06, with a Debt / Equity ratio of 0.15.

    Current Ratio

    n/a
    		 7.06

    Quick Ratio

    n/a
    		 7.06

    Debt / Equity

    n/a
    		 0.15

    Debt / EBITDA

    n/a
    		 -0.29

    Debt / FCF

    n/a
    		 -0.36

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $203.33

    Profits Per Employee

    n/a
    		 $-1,143,313.33

    Employee Count

    n/a
    		 300

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -77.34% in the last 52 weeks. The beta is -0.27, so Lyell Immunopharma's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.27

    52-Week Price Change

    n/a
    		 -77.34%

    50-Day Moving Average

    n/a
    		 9.03

    200-Day Moving Average

    n/a
    		 16.21

    Relative Strength Index (RSI)

    n/a
    		 61.96

    Average Volume (20 Days)

    n/a
    		 69,698

    Income Statement

    In the last 12 months, Lyell Immunopharma had revenue of 61K and earned -342.99M in profits. Earnings per share was -1.31.

    Revenue

    n/a
    		 61K

    Gross Profit

    n/a
    		 61K

    Operating Income

    n/a
    		 -358.75M

    Net Income

    n/a
    		 -342.99M

    EBITDA

    n/a
    		 -200.64M

    EBIT

    n/a
    		 -220.27M

    Earnings Per Share (EPS)

    n/a
    		 -1.31
    Full Income Statement

    Balance Sheet

    The company has 105.6M in cash and 58.97M in debt, giving a net cash position of 46.63M.

    Cash & Cash Equivalents

    n/a
    		 105.6M

    Total Debt

    n/a
    		 58.97M

    Net Cash

    n/a
    		 46.63M

    Retained Earnings

    n/a
    		 -1.35B

    Total Assets

    n/a
    		 429.8M

    Working Capital

    n/a
    		 267.89M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -162.39M and capital expenditures -464K, giving a free cash flow of -162.86M.

    Operating Cash Flow

    n/a
    		 -162.39M

    Capital Expenditures

    n/a
    		 -464K

    Free Cash Flow

    n/a
    		 -162.86M

    FCF Per Share

    n/a
    		 -0.62
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -588122.95% and -562285.25%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -588122.95%

    Pretax Margin

    n/a
    		 -562285.25%

    Profit Margin

    n/a
    		 -562285.25%

    EBITDA Margin

    n/a
    		 -328922.95%

    EBIT Margin

    n/a
    		 -588122.95%

    FCF Margin

    n/a
    		 -266980.33%

    Dividends & Yields

    LYEL does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for LYEL is $20, which is 77.9% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $20

    Price Target Difference

    n/a
    		 77.9%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 2
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Jun 2, 2025. It was a backward split with a ratio of 1:20.

    Last Split Date

    n/a
    		 Jun 2, 2025

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:20

    Scores

    Altman Z-Score

    n/a
    		 -4.73

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist